Novel CAR-T Assets in MM; Arcellx, Gracell, and OriCell Present Updated Clinical Results in R/R MM; ASCO 2022 Analysis 4
ASCO 2022 Analysis 4: Arcellx, Gracell, and OriCell presented clinical updates from their novel CAR-Ts in r/r MM. Additionally, Arcellx held an ASCO 2022 Investor Event. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: